Moolec Science dismisses PwC as auditor following voluntary winding-up approval
Bitget2026/10/21 21:12- Moolec Science dismissed PwC as its independent auditor effective October 21, 2026, deeming its continued engagement unnecessary.
- Shareholders voted for a voluntary winding-up on October 20, 2026.
- A previously disclosed material weakness concerned business combination accounting, specifically the timely completion of the purchase price allocation.
- PwC's audit report for the fiscal year ended June 30, 2025, flagged substantial doubt about the company's ability to continue operating.
- No accounting or auditing disagreements arose during the two most recent fiscal years or subsequent interim period through October 21, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
